Research
Evidence reviews of the drugs sold online — semaglutide, tirzepatide, and what the trials behind them actually measured. No secondary summaries: every claim traced to the trial, the label, or the paper of record.
6 articles
- Safety
GLP-1 drugs and sexual function: what has actually been measured
The weight-loss trials did not measure libido or erectile function. What exists is a reporting signal, a cohort analysis pointing the other way, and case reports.
6 min read - Safety
GLP-1 drugs in menopause: a large audience and an empty subgroup
Women were 79% of one trial population at a mean age of 46, and no published trial has reported outcomes by menopausal status.
6 min read - Evidence
Muscle loss on a GLP-1: what the body-composition data shows
The best-controlled measurement puts the lean-mass change at −2.5 kg with a confidence interval that crosses zero. The certainty in the debate is not in the data.
6 min read - Evidence
What happens when you stop: the withdrawal evidence
Three randomized withdrawal studies asked what happens after the drug stops. Participants regained two thirds of the loss within a year.
7 min read - Safety
Tirzepatide and oral contraception: what the one study found
A single pharmacokinetic study cut peak concentrations by up to 66% and total exposure by around 20%. Those two numbers mean different things.
5 min read - Evidence
The escalation window: titration schedules and how often nausea stops people
The first twenty weeks are where the dose climbs, where the side effects cluster, and where a dose-priced seller starts charging more.
6 min read